Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 29, 2007
- BUSINESS NEWS IN BRIEF
October 29, 2007
- OPINION／Why Problems Are Always Opportunities
October 29, 2007
- Pfizer Holds Career Planning Course for Female MRs
October 29, 2007
- Development of More Switch OTC Drugs Essential
October 29, 2007
- AstraZeneca Works to Create Easier-to-Work Environment for Female MRs
October 29, 2007
- Paltac to Stimulate OTC Drug Market by Merging with Kobashou
October 29, 2007
- MR Education Center Considers Radical Reform of MR Education System
October 29, 2007
- R&D NEWS IN BRIEF
October 29, 2007
- SEMINAR／Generics to Obtain 1/3 of Market for Antibacterials in 2016: Datamonitor
October 29, 2007
- Korosho to Increase Multinational Joint Trial Participation Rate under 5-Year Plan
October 29, 2007
- Consumption of EPO Decreased in 40% of Patients
October 29, 2007
- OHARA Pharm. Strengthens Product, Information Supply Systems
October 29, 2007
- Merck Ties UP with ImClone, BMS for Erbitux in Japan
October 29, 2007
- Alcon to Invest US$3 Bil. in R&D over the Next 5 Years
October 22, 2007
- BUSINESS NEWS IN BRIEF
October 22, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 22, 2007
- Diovan Keeps Top Position for 5 Consecutive Months
October 22, 2007
- MEDICAL DEVICE NEWS IN BRIEF
October 22, 2007
- Major Domestic Companies Must Overcome 2010 Crisis
October 22, 2007
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…